BioCentury
ARTICLE | Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

October 5, 2018 8:19 PM UTC

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not significantly improve investigator-rated symptoms of PTSD as measured by Clinician-Administered PTSD Scale (CAPS-5) score from baseline to week 12 vs. placebo. The double-blind, U.S. and Australian trial enrolled 193 patients to receive placebo or twice-daily 150, 300 or 600 mg doses of BNC210. BNC210 is a negative allosteric modulator of nicotinic acetylcholine receptor α 7 (CHRNA7)...